Biocon appoints Suresh Subramanian as Head of Branded Formulations India Business

India Infoline News Service | Mumbai | September 19, 2016, 10:46 IST

Suresh has over 30 years of experience in the pharmaceuticals market, having worked in India and Thailand for MNCs such as GlaxoSmithKline, Novartis, AstraZeneca and Pfizer.

Biocon Limited
Biocon Ltd, Asia's premier biopharmaceuticals company, announced today that Suresh Subramanian has been appointed as Head of the Company's Branded Formulations (India) business.

Suresh has over 30 years of experience in the pharmaceuticals market, having worked in India and Thailand for MNCs such as GlaxoSmithKline, Novartis, AstraZeneca and Pfizer. Over the years, he has played multiple leadership roles in Business Development, Marketing, Sales and Strategy. He has a rich experience of multiple product launches, business optimization, cost control, talent development and performance  management.

Suresh has managed a wide portfolio spanning diverse therapy areas such as Neurosciences, Respiratory, Cardiology, Oncology, Critical Care, Gastro-lntestinal, Ophthalmology, Pain & Inflammation and Women's Health in the  Indian market. He has also played a critical role in  mapping the pharma opportunity in India as  part of the Steering Committee for  McKinsey's  India  Pharma 2020 report.

Kiran Mazumdar-Shaw, CMD, Biocon, said, "We are extremely delighted to have Suresh Subramanian lead our Branded Formulations business in India. Suresh has deep expertise in diverse therapy areas including Oncology, Cardiology and Critical Care and has a proven track record of delivering robust business growth. Weare sure, under his leadership, our Branded Formulations business will evolvefurther and become a strong value builderfor Biocon."

Biocon's Branded Formulations (India) business is a biologics-led, specialty pharma business focused on the chronic therapy areas of diabetes, cancer and autoimmune conditions. Many of its key brands are leaders in their respective categories. ALZUMAb, a novel biologic developed by Biocon, is the world's first anti-CD6 monoclonal antibody introduced in India for Psoriasis. lnsugen is the largest Indian Insulins brand, while Basalog is a leading Indian Insulin Glargine brand. CANMAb an affordable Trastuzumab for metastatic breast cancer has benefitted several thousand patients in India.

Suresh Subramanian is a Physics graduate and has a Masters in Marketing Management from Mumbai University.
BSE 924.55 [46.95] ([4.83]%)

***Note: This is a NSE Chart

 

Advertisements

  • Get your free IIFL Demat & Trading A/c now...Click here
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.